Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H30N2O3S.CH4O3S |
| Molecular Weight | 522.677 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.[H][C@]12CN(CC3(O)CC4=C(C3)C=CC=C4)C[C@@]1([H])[C@]2(CC)C5=CC=CC(NS(C)(=O)=O)=C5
InChI
InChIKey=JGFCIQDZOHYVLW-WNYOANAGSA-N
InChI=1S/C24H30N2O3S.CH4O3S/c1-3-24(19-9-6-10-20(11-19)25-30(2,28)29)21-14-26(15-22(21)24)16-23(27)12-17-7-4-5-8-18(17)13-23;1-5(2,3)4/h4-11,21-22,25,27H,3,12-16H2,1-2H3;1H3,(H,2,3,4)/t21-,22+,24+;
CP-866087 is a mu opioid receptor antagonist, discovered by Pfizer. The compound was able to antagonize the effect of morphine in a rodent tail flick assay and produced a dose-dependent decrease in alcohol intake in alcohol-preferring rats. The compound was investigated in clinical trials for the treatment of obesity, alcoholism and female sexual arousal disorder. In the later study, although improvements were seen with CP-866,087 in the key efficacy endpoints, there was no clinical treatment benefit over placebo.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DBSALT002154
Created by
admin on Fri Dec 15 15:56:26 GMT 2023 , Edited by admin on Fri Dec 15 15:56:26 GMT 2023
|
PRIMARY | |||
|
15606276
Created by
admin on Fri Dec 15 15:56:26 GMT 2023 , Edited by admin on Fri Dec 15 15:56:26 GMT 2023
|
PRIMARY | |||
|
519052-03-0
Created by
admin on Fri Dec 15 15:56:26 GMT 2023 , Edited by admin on Fri Dec 15 15:56:26 GMT 2023
|
PRIMARY | |||
|
C11T0WZN2R
Created by
admin on Fri Dec 15 15:56:26 GMT 2023 , Edited by admin on Fri Dec 15 15:56:26 GMT 2023
|
PRIMARY | |||
|
1349414-57-8
Created by
admin on Fri Dec 15 15:56:26 GMT 2023 , Edited by admin on Fri Dec 15 15:56:26 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY |
ACTIVE MOIETY
SUBSTANCE RECORD
